Immune dysregulation mechanisms of persistent post-COVID19 olfactory dysfunction
- Institution
- BRIGHAM AND WOMEN'S HOSPITAL, MA
- Principal investigator
- Lora Bankova
- Funding
- $634K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY: The sudden loss of smell and taste are among the defining features of COVID-19 that set it apart from other viral respiratory syndromes with an incidence of up to 70% with some SARSCoV2 variants. Importantly, in some patients smell and taste disturbances persist for longer than 12 months after recovery from COVID-19. Furthermore, classical anti-inflammatory treatment therapies are ineffective for COVID19 chemosensory dysfunction. To inform targeted treatments, it is critical to elucidate the specific pathways that lead to persistent disruption of chemosensory function. Our preliminary data show that persistent COVID19 chemosensory dysfunction involves persistently disordered neuroepithelial composition and infiltration with immune cells with features of immunosuppressive macrophages. The dysregulated inflammatory milieu prominently features linoleic acid metabolites and glioma-associated proteins with direct effect on olfactory stem cell proliferation and differentiation and olfactory sensory neuron survival. This study will determine how the inflammatory but steroid-resistant immune cells drive chemosensory dysfunction that plagues patients with persistent COVID19 disruption of smell and taste. In Aim 1 we will define the phenotype of the infiltrating immune cells using both transcriptional and mediator studies. In Aim 2, we will determine how immune mediators defined in Aim 1 disrupt olfactory stem cell and sensory neuron development and apoptosis trajectories using a mouse in vitro system and relate these findings to the disordered epithelial composition of subjects with persistent COVID19 chemosensory dysfunction. Thus, we use complementary approaches with molecular tools and cell systems and samples from carefully phenotyped human subjects. The studies should reveal new potential strategies for therapeutic development that are based on the novel underlying mechanism that we identified here.
LOADING MOONBASE SCORE
Questions for BRIGHAM AND WOMEN'S HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Brigham and Women'S HospitalNot yet scored
Allergen-elicited signaling cascades in olfactory microvillous tuft cells
Lora Bankova · $216K · 2024–2026
- NIH · Brigham and Women'S Hospital64
Making the invisible visible: An automated clinical decision support tool for Intimate Partner Violence Risk and Severity Prediction (AIRS)
Bharti Khurana · $796K · 2022–2027
- NIH · Brigham and Women'S Hospital60
Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention
Holly Elizabeth Rawizza · $190K · 2022–2028